Earnings Routine +

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

Theralase Confirms Bladder Cancer Submission Timeline Amidst Continued Burn Rate

By The Northwire Desk — AI Analysis May 04, 2026 · 17:23 TLT · 0.3 Theralase Technologies Inc.

Executive Summary

Financial Performance: Released 2025 Annual Financial Statements reporting a net loss of $4.12 million, slightly improved from $4.26 million in 2024. Total revenue decreased 21% to $816,468. Gross margin improved to 62%.
Clinical Study II Update: Interim data for Ruvidar® (TLD-1433) shows a 65.2% Complete Response (CR) rate in evaluable patients with BCG-Unresponsive NMIBC. Durability analysis indicates 40.4% maintained CR at 450 days, with one patient demonstrating CR for 7 years.
Regulatory Timeline: Plans to submit New Drug Submissions (NDS) and New Drug Applications (NDA) to Health Canada and the FDA in Q3 2026. Regulatory decisions anticipated in H1 2027.
Strategic Collaboration: Announced expansion of clinical program via agreement with Ferring Pharmaceuticals to evaluate Ruvidar® in combination with Adstiladrin® (Cohort 2).
Safety Profile: No Serious Adverse Events (SAEs) directly related to the Study Drug or Device. Treatment Emergent Adverse Events included urinary frequency, hematuria, and urgency.

Material Impact

Confirmation of Expectations: The clinical data (65.2% CR rate) aligns closely with interim reports from February 2026 (64.3-65.2%) and November 2025 (64.3%). This is not new information but a formal confirmation of the annual report.
Regulatory Pathway: The Q3 2026 submission timeline was previously outlined in February 2026 news ("Rolling review beginning Q3 2026"). No change to the critical path for approval.
Ferring Collaboration: The collaboration with Ferring Pharmaceuticals was announced on January 12, 2026. This release confirms the expansion into Cohort 2 but does not introduce a new strategic partner or investment.
Financial Health: The reduction in net loss ($4.12M vs $4.25M) and R&D expenses (down 9%) indicates cost control, but revenue remains low ($816k). This is consistent with the pre-revenue clinical stage profile.
Market Reaction Context: Price data ends May 1, 2026 ($0.31), prior to this news release on May 4. The stock had rallied from $0.15 (Dec 2025) to $0.39 (April 2026). This news serves as a validation of the rally thesis rather than a new catalyst.
Verdict: The information is positive but largely expected by investors following the Q4 2025 and Q1 2026 announcements regarding Study II completion and Ferring partnership. It reduces uncertainty regarding the submission date but does not alter the fundamental risk/reward profile significantly compared to April preclinical Rutherrin news.

TLT · Price

Company Overview

Company: Theralase Technologies Inc. (TLT).
Flagship Project: Ruvidar® (TLD-1433), a light-activated small molecule therapy for Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma in Situ (CIS).
Secondary Project: Rutherrin®, an X-ray-activated ruthenium-based drug for Muscle-Invasive Bladder Cancer (MIBC) and other solid tumors. Currently in preclinical/early clinical development.
Technology: Photodynamic Therapy (PDT) utilizing specific wavelengths of light to activate the drugs, inducing cytotoxicity and immunogenic cell death.
Development Stage: Ruvidar® is in Phase II registrational trials for NMIBC; Rutherrin® is in preclinical/Phase 0 planning.

More from Theralase Technologies Inc.